Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Immunotherapeutic Cancer Drug Fails to Meet Primary Endpoint in PIII Study: Merck Serono
December 25, 2012
- Mortality Rate of Patients After Major Bleeds Significantly Lower with Dabigatran: BI
December 25, 2012
- Safety of Xarelto Found to Be “Consistent with Clinical Trial Data” in EPPV: Bayer Yakuhin
December 25, 2012
- Generic-only Companies Which Rely on Wholesales Worried About Decline in Their Relative Position with Wholesalers
December 25, 2012
- Increasing Competition in AD Drug Market; Sales of Over 240 Billion Yen Predicted by 2020
December 25, 2012
- Novartis Files for Approval of Combination Drug of Rasilez, CCB
December 21, 2012
- Nexium Dominates No.1, 2 Ranking in HP Market for 3rd Consecutive Month: Rep Track Survey
December 21, 2012
- Bayer Files for Approval of Radioactive Anticancer Agent in US and Europe
December 20, 2012
- Dolutegravir Filed for Approval in Europe, the US and Canada: Shionogi
December 20, 2012
- Sanofi’s JAK2 Inhibitor Improves Symptoms in Patients with MF in PII Trial
December 20, 2012
- Carsten Brunn to Take Over as President of Bayer Yakuhin in March 2013
December 20, 2012
- Eisai Transfers US Rights for Brain Tumor Treatment to Arbor Pharm
December 19, 2012
- Crestor Patent Upheld by US Court of Appeals for the Federal Circuit: Shionogi
December 19, 2012
- Takeda to Sell URL Pharma’s Generic Drug Business to Caraco
December 19, 2012
- Elmed Eisai, Kobayashi Kako Allegra Generics Not Launched on December 14
December 18, 2012
- Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
- Eisai to Form Alliance with University College London for Drug Discovery Research
December 18, 2012
- Chugai to Adopt IFRS from FY2013
December 18, 2012
- Takeda Launches Phone Service to Support Patients’ Drug Administration
December 17, 2012
- Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…